Dive Brief:
- Insulet received clearance from the Food and Drug Administration for a tubeless insulin pump designed for people with Type 2 diabetes who are in the early stages of insulin treatment.
- The device, called Omnipod GO, is intended to replace daily injections of long-acting insulin.
- CEO Jim Hollingshead said the device was designed to serve more than 3 million people who use basal insulin or are transitioning to insulin therapy to treat Type 2 diabetes.
Dive Insight:
Insulet’s latest tubeless pump is designed to serve people early in their Type 2 diabetes treatment, by starting them on pod therapy rather than daily injections, the company said in a Tuesday statement. If, later on, a patient needs both basal and bolus insulin, they could transition to the company’s Omnipod DASH pump.
“Our goal is to help people with type 2 diabetes successfully shift to insulin therapy with a product that fundamentally changes how they feel about diabetes management,” Hollingshead said in a statement. “We’re excited to bring this new solution to market and deliver on our mission to simplify life for people with diabetes.”
The Omnipod GO provides rapid-acting insulin at a fixed rate over three days. It includes pre-programmed daily rates ranging from 10 units to 40 units per day, and can operate without a handheld device needed to control the pod.
Insulet plans to start selling Omnipod Go in the U.S. in 2024. People will be able to access it through their pharmacy benefit, according to the company. The device is cleared for people with Type 2 diabetes who are 18 or older, and who would typically take daily insulin injections.
